{"nctId":"NCT00433160","briefTitle":"Phase 3 Clinical Trial of Teriparatide in Japan","startDateStruct":{"date":"2007-01"},"conditions":["Osteoporosis"],"count":207,"armGroups":[{"label":"Teriparatide","type":"EXPERIMENTAL","interventionNames":["Drug: Teriparatide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Teriparatide","Drug: Placebo"]}],"interventions":[{"name":"Teriparatide","otherNames":["LY333334","Forteo","Forsteo"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese patients diagnosed with osteoporosis\n* Aged 55 or older\n* Patients who are at high risk for fracture\n\nExclusion Criteria:\n\n* History of metabolic bone disorders other than primary osteoporosis\n* History of malignant neoplasm in the 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated.\n* Severe or chronically disabling conditions other than osteoporosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4)","description":"Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.82","spread":"5.36"},{"groupId":"OG001","value":"0.04","spread":"4.34"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)","description":"Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.23","spread":"5.74"},{"groupId":"OG001","value":"0.11","spread":"4.42"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at Total Hip","description":"Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.66","spread":"4.22"},{"groupId":"OG001","value":"-0.22","spread":"3.38"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at Femoral Neck","description":"Percent change in bone mineral density at femoral neck from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":"6.01"},{"groupId":"OG001","value":"0.46","spread":"3.89"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP)","description":"Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.67","spread":"49.85"},{"groupId":"OG001","value":"-9.58","spread":"14.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.58","spread":"66.58"},{"groupId":"OG001","value":"-16.89","spread":"17.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114.12","spread":"112.04"},{"groupId":"OG001","value":"-19.10","spread":"29.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116.11","spread":"139.72"},{"groupId":"OG001","value":"-14.18","spread":"29.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111.74","spread":"134.38"},{"groupId":"OG001","value":"-13.82","spread":"28.42"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP)","description":"Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.74","spread":"37.86"},{"groupId":"OG001","value":"-9.63","spread":"33.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.23","spread":"49.05"},{"groupId":"OG001","value":"-16.97","spread":"40.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.60","spread":"43.44"},{"groupId":"OG001","value":"-28.46","spread":"23.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.69","spread":"58.12"},{"groupId":"OG001","value":"-32.24","spread":"46.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.32","spread":"56.06"},{"groupId":"OG001","value":"-28.34","spread":"46.96"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Biochemical Markers of Bone Metabolism - Serum Type I Collagen Crosslinked C-telopeptide (CTX)","description":"Percent change in serum type I collagen crosslinked C-telopeptide (CTX) from baseline to the individual visits and last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"40.73"},{"groupId":"OG001","value":"-2.05","spread":"28.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.52","spread":"69.52"},{"groupId":"OG001","value":"-3.56","spread":"27.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.27","spread":"110.54"},{"groupId":"OG001","value":"4.39","spread":"37.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.81","spread":"124.23"},{"groupId":"OG001","value":"13.50","spread":"39.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.41","spread":"119.61"},{"groupId":"OG001","value":"11.64","spread":"38.61"}]}]}]},{"type":"SECONDARY","title":"Vertebral Fractures by Central X-ray Assessment","description":"Number of vertebral fractures observed from Visit 1 (study entry) through Visit 19 (Week 52). All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Fractures by Investigators Assessment","description":"Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be \"fragility\" if they occurred without trauma.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Back Pain Severity","description":"Severity of back pain at baseline, individual visits and the last measurement point. Back pain was measured on a scale of 1 (none) to 4 (severe).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4) During Open Label Phases at 76 Weeks and 104 Weeks","description":"Percent change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.93","spread":"5.79"},{"groupId":"OG001","value":"6.39","spread":"4.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.42","spread":"6.12"},{"groupId":"OG001","value":"9.11","spread":"5.14"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) During Open Label Phases at 76 Weeks and 104 Weeks","description":"Percent change in bone mineral density at lumbar spine (L1-L4) from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.24","spread":"5.86"},{"groupId":"OG001","value":"6.63","spread":"4.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.01","spread":"6.41"},{"groupId":"OG001","value":"9.46","spread":"5.35"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at Total Hip During Open Label Phases at 76 Weeks and 104 Weeks","description":"Percent change in bone mineral density (BMD) at total hip from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"3.79"},{"groupId":"OG001","value":"1.64","spread":"4.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","spread":"3.98"},{"groupId":"OG001","value":"2.46","spread":"3.54"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Bone Mineral Density (BMD) at Femoral Neck During Open Label Phases at 76 Weeks and 104 Weeks","description":"Percent change in bone mineral density at femoral neck from baseline to the last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":"4.45"},{"groupId":"OG001","value":"1.17","spread":"4.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.26","spread":"4.25"},{"groupId":"OG001","value":"2.19","spread":"4.81"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Biochemical Markers of Bone Metabolism - Serum Procollagen I N-terminal Propeptide (PINP) During Open Label Phases at 76 Weeks and 104 Weeks","description":"Percent change in serum procollagen I N-terminal propeptide (PINP) from baseline to the individual visits and last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115.45","spread":"174.07"},{"groupId":"OG001","value":"97.28","spread":"131.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.71","spread":"112.48"},{"groupId":"OG001","value":"134.89","spread":"180.76"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Biochemical Markers of Bone Metabolism - Serum Bone-specific Alkaline Phosphatase (BAP) During Open Label Phases at 76 Weeks and 104 Weeks","description":"Percent change in serum bone-specific alkaline phosphatase (BAP) from baseline to the individual visits and last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.49","spread":"66.40"},{"groupId":"OG001","value":"15.71","spread":"64.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.52","spread":"54.38"},{"groupId":"OG001","value":"16.45","spread":"71.72"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Biochemical Markers of Bone Metabolism - Serum Type I Collagen Crosslinked C-telopeptide (CTX) During Open Label Phases at 76 Weeks and 104 Weeks","description":"Percent change in serum type I collagen crosslinked C-telepeptide (CTX) from baseline to the individual visits and last measurement point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.85","spread":"137.13"},{"groupId":"OG001","value":"86.98","spread":"132.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.39","spread":"111.97"},{"groupId":"OG001","value":"72.84","spread":"100.91"}]}]}]},{"type":"SECONDARY","title":"Vertebral Fractures by Central X-ray Assessment During Entire Study Period of 104 Weeks","description":"Number of vertebral fractures observed from Visit 1 (study entry) through 104 weeks. All new or worsened vertebral fractures were defined as a deterioration of at least one grade in a semiquantitative score by X-ray assessment. Number of subjects with fractures and number of fractured vertebra(e) were counted.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Fractures by Investigators Assessment During Entire Study Period of 104 Weeks","description":"Vertebral and nonvertebral fractures assessed by the investigator or subinvestigator after starting the study treatment. Traumatic fractures were those caused by falling from above standing height or a high velocity (car) accident. Fractures were assessed to be \"fragility\" if they occurred without trauma.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Back Pain Severity During Open Label Phases at 76 Weeks and 104 Weeks","description":"Severity of back pain at 76 weeks and 104 weeks. Back pain was measured on a scale of 1 (none) to 4 (severe).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":136},"commonTop":["Nasopharyngitis","Back pain","Fall","Contusion","Osteoarthritis"]}}}